Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DM199 in Patients With Diabetes and Chronic Kidney Disease
NCT03795389Phase 1Completed
- Sponsor
- DiaMedica Therapeutics
- Start
- Feb 2019
- Primary completion
- Jul 2019
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of rinvecalinase alfa in chronic kidney disease (CKD), type 1 diabetes mellitus (T1D) and type 2 diabetes mellitus (T2DM) (4 cohorts), sponsored by DiaMedica Therapeutics. Primary endpoints: Incidence, severity, and causality of adverse events at 11 days, Tolerability assessed by incidence and severity of AEs at 11 days and 2 more. Started Feb 2019; status: completed.
02
Drugs
rinvecalinase alfa
03
Conditions
chronic kidney disease (CKD)type 1 diabetes mellitus (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03795389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03795389.